NASDAQ:ESPR - Esperion Therapeutics Stock Price, Price Target & More

$73.69 -0.47 (-0.63 %)

(As of 04/22/2018 06:18 AM ET)

Previous Close$73.69

Today's Range$72.88 - $75.6799

52-Week Range$30.95 - $82.68

Volume293,749 shs

Average Volume536,679 shs

Market Capitalization$1.97 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.51

About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:ESPR

CUSIPN/A

Webwww.esperion.com

Phone734-887-3903

Debt

Debt-to-Equity RatioN/A

Current Ratio6.15%

Quick Ratio6.15%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book Value$9.34 per share

Price / Book7.89

Profitability

EPS (Most Recent Fiscal Year)($6.98)

Net Income$-166,980,000.00

Net MarginsN/A

Return on Equity-76.84%

Return on Assets-67.42%

Miscellaneous

Employees57

Outstanding Shares26,750,000

How to Become a New Pot Stock Millionaire

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics (NASDAQ:ESPR) released its quarterly earnings data on Tuesday, February, 20th. The biopharmaceutical company reported ($1.44) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.36. During the same period last year, the company posted ($1.29) earnings per share. View Esperion Therapeutics' Earnings History.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Esperion Therapeutics.

What price target have analysts set for ESPR?

13 brokerages have issued twelve-month target prices for Esperion Therapeutics' shares. Their predictions range from $64.00 to $153.00. On average, they anticipate Esperion Therapeutics' share price to reach $96.3077 in the next twelve months. View Analyst Ratings for Esperion Therapeutics.

What are Wall Street analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:

1. Chardan Capital analysts commented, "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors." (12/5/2017)
2. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (8/23/2017)

Who are some of Esperion Therapeutics' key competitors?

Some companies that are related to Esperion Therapeutics include FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Tesaro (TSRO), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Acadia Pharmaceuticals (ACAD), Akorn (AKRX) and Puma Biotechnology (PBYI).

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the folowing people:

Mr. Timothy M. Mayleben, CEO, Pres & Director (Age 57)
Dr. Narendra D. Lalwani Ph.D., FAHA, DABT, MBA, Chief Operating Officer and Exec. VP of R&D (Age 65)
Dr. Mary P. McGowan M.D., Chief Medical Officer (Age 58)
Mr. Richard B. Bartram, CFO, Principal Accounting Officer & Corp. Sec.
Ms. Marianne Andreach, Sr. VP of Product Planning

Has Esperion Therapeutics been receiving favorable news coverage?

Media coverage about ESPR stock has trended positive recently, Accern reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Esperion Therapeutics earned a daily sentiment score of 0.30 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include DOMAIN PARTERS VII L P (4.20%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani, Nicole Vitullo, Roger S Newton and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $73.69.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $1.97 billion. The biopharmaceutical company earns $-166,980,000.00 in net income (profit) each year or ($6.98) on an earnings per share basis. Esperion Therapeutics employs 57 workers across the globe.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]

MarketBeat Community Rating for Esperion Therapeutics (ESPR)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		362 (Vote Outperform)
Underperform Votes:		294 (Vote Underperform)
Total Votes:		656

MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Esperion Therapeutics (NASDAQ:ESPR) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

13 Wall Street analysts have issued ratings and price targets for Esperion Therapeutics in the last 12 months. Their average twelve-month price target is $96.3077, suggesting that the stock has a possible upside of 30.69%. The high price target for ESPR is $153.00 and the low price target for ESPR is $64.00. There are currently 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.77	2.77	2.77	2.69
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 8 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 8 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 8 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$96.3077	$90.6154	$77.2308	$58.9167
Price Target Upside:	30.69% upside	20.40% upside	0.04% upside	9.02% upside

Esperion Therapeutics (NASDAQ:ESPR) Consensus Price Target History

Price Target History for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/19/2018	Northland Securities	Boost Price Target	Buy	$100.00 -> $121.00	Low
3/27/2018	Chardan Capital	Boost Price Target	Neutral -> Neutral	$75.00 -> $100.00	Low
3/9/2018	Deutsche Bank	Boost Price Target	Buy	$100.00	Low
3/8/2018	JMP Securities	Boost Price Target	Outperform	$60.00 -> $153.00	High
3/7/2018	Stifel Nicolaus	Set Price Target	Buy	$105.00	High
2/21/2018	UBS	Set Price Target	Neutral -> Neutral	$88.00 -> $90.00	High
2/21/2018	JPMorgan Chase	Reiterated Rating	Neutral -> Neutral	$55.00 -> $65.00	High
2/21/2018	Needham & Company LLC	Reiterated Rating	Strong-Buy -> Strong-Buy	$81.00 -> $94.00	Low
1/22/2018	Citigroup	Downgrade	Buy -> Neutral	$77.00 -> $96.00	Low
1/17/2018	Credit Suisse Group	Initiated Coverage	Outperform -> Outperform	$103.00	Low
1/5/2018	Bank of America	Upgrade	Neutral -> Buy	$76.00	High
9/7/2017	Cowen	Initiated Coverage	Outperform	$64.00	Low
8/21/2017	Jefferies Group	Reiterated Rating	Buy	$85.00	Low
3/20/2017	Royal Bank of Canada	Reiterated Rating	Hold	$45.00	High
8/31/2016	Barclays	Set Price Target	Hold	$13.00	N/A
7/5/2016	WallachBeth Capital	Downgrade	Buy -> Hold	$35.00	N/A
6/29/2016	Lake Street Capital	Lower Price Target	Buy	$80.00 -> $27.00	N/A

(Data available from 4/22/2016 forward)

Esperion Therapeutics (NASDAQ:ESPR) Earnings History and Estimates Chart

Earnings by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR) Earnings Estimates

2018 EPS Consensus Estimate: ($5.51)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($1.42)	($1.42)	($1.42)
Q2 2018	1	($1.38)	($1.38)	($1.38)
Q3 2018	1	($1.35)	($1.35)	($1.35)
Q4 2018	1	($1.36)	($1.36)	($1.36)

Esperion Therapeutics (NASDAQ ESPR) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
5/2/2018		($1.56)			N/A
2/20/2018	Q4 2017	($1.80)	($1.44)	View	N/A
11/7/2017	Q3 2017	($1.79)	($1.86)	View	N/A
8/8/2017	Q2 2017	($1.67)	($1.92)	View	Listen
5/1/2017	Q1 2017	($1.4410)	($1.80)	View	N/A
2/22/2017	12/31/2016	($1.24)	($1.29)	View	N/A
11/3/2016	Q3	($0.82)	($0.77)	View	N/A
8/4/2016	Q2	($0.78)	($0.62)	View	N/A
5/4/2016	Q116	($0.74)	($0.65)	View	N/A
2/25/2016	Q4	($0.6050)	($0.58)	View	N/A
11/5/2015	Q3	($0.60)	($0.57)	View	N/A
8/6/2015	Q215	($0.58)	($0.55)	View	N/A
5/7/2015	Q115	($0.54)	($0.56)	View	N/A
3/5/2015	Q4 2014	($0.54)	($0.49)	View	N/A
11/10/2014	Q3 2014	($0.68)	($0.64)	View	N/A
8/12/2014	Q214	($0.55)	($0.60)	View	N/A
5/12/2014	Q1 2014	($0.62)	($0.51)	View	N/A
3/5/2014		($0.50)	($0.63)	View	N/A
11/6/2013	Q3 2013	($0.41)	($0.34)	View	N/A
8/12/2013	Q2 2013		($12.53)	View	N/A

(Earnings results data provided by Zacks Investment Research)

Esperion Therapeutics (NASDAQ:ESPR) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Esperion Therapeutics (NASDAQ ESPR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 32.50%
Institutional Ownership Percentage: 91.66%

Insider Trading History for Esperion Therapeutics (NASDAQ:ESPR)

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ ESPR) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/29/2018	Roger S Newton	Director	Sell	25,000	$72.37	$1,809,250.00	639,682
1/25/2018	Nicole Vitullo	Director	Sell	11,674	$71.79	$838,076.46	3,177
12/6/2017	Nicole Vitullo	Director	Sell	9,326	$53.85	$502,205.10	2,472
3/22/2017	Dov A Md Goldstein	Director	Sell	800,000	$41.66	$33,328,000.00
3/21/2017	Gilbert S Omenn	Director	Buy	1,000	$42.26	$42,260.00	10,000
11/1/2016	Narendra D Lalwani	COO	Buy	5,000	$9.93	$49,650.00	5,000
7/6/2016	Mark E Mcgovern	Director	Buy	5,000	$10.00	$50,000.00	600
5/4/2016	Timothy M Mayleben	CEO	Buy	7,000	$14.85	$103,950.00	41,614
3/1/2016	Gilbert S Omenn	Director	Buy	5,000	$15.28	$76,400.00	10,000
1/27/2016	Timothy M Mayleben	CEO	Buy	3,600	$15.88	$57,168.00	34,614
1/15/2016	Timothy M Mayleben	CEO	Buy	7,200	$14.08	$101,376.00	31,014
4/24/2015	Dov A Md Goldstein	Director	Sell	217,469	$108.22	$23,534,495.18
11/18/2014	Patrick G Enright	Director	Sell	487,130	$32.78	$15,968,121.40
10/21/2014	Parters Vii L P Domain	Major Shareholder	Buy	500,000	$20.00	$10,000,000.00
10/7/2014	Longitude Capital Partners, Ll	Major Shareholder	Sell	11,927	$30.04	$358,287.08
7/1/2013	Brian H Dovey	Major Shareholder	Buy	285,714	$14.00	$3,999,996.00
7/1/2013	Daniel Janney	Director	Buy	235,714	$14.00	$3,299,996.00
7/1/2013	Roger S Newton	Chairman	Buy	42,346	$14.00	$592,844.00
7/1/2013	Timothy M Mayleben	CEO	Buy	5,000	$14.00	$70,000.00

(Data available from 1/1/2013 forward)

Esperion Therapeutics (NASDAQ ESPR) News Headlines

Source:

Date	Headline
	Esperion Therapeutics' (ESPR) "Buy" Rating Reiterated at UBS www.americanbankingnews.com - April 20 at 3:36 PM
	Esperion Therapeutics (ESPR) PT Raised to $121 at Northland to Reflect High Confidence in P3 Outcomes www.streetinsider.com - April 20 at 8:51 AM
	Northland Securities Boosts Esperion Therapeutics (ESPR) Price Target to $121.00 www.americanbankingnews.com - April 19 at 3:36 PM
	Esperion Therapeutics (ESPR) Expected to Announce Earnings of -$1.56 Per Share www.americanbankingnews.com - April 15 at 1:19 AM
	Esperion Therapeutics (ESPR) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - April 12 at 3:31 PM
	Esperion Therapeutics (ESPR) Given a $64.00 Price Target at Deutsche Bank www.americanbankingnews.com - April 11 at 7:18 PM
	Esperion Therapeutics (ESPR) Receives "Buy" Rating from Stifel Nicolaus www.americanbankingnews.com - April 11 at 5:35 PM
	Esperion Therapeutics (ESPR) Earns Buy Rating from Stifel Nicolaus www.americanbankingnews.com - April 8 at 12:40 AM
	Esperion Therapeutics' (ESPR) "Buy" Rating Reiterated at Northland Securities www.americanbankingnews.com - April 8 at 12:40 AM
	Esperion Therapeutics (ESPR) Rating Increased to Buy at ValuEngine www.americanbankingnews.com - April 3 at 4:16 PM
	Insider Selling: Esperion Therapeutics (ESPR) Director Sells 25,000 Shares of Stock www.americanbankingnews.com - March 29 at 10:10 PM
	Pre-Market Technical Scan on Biotech Equities -- Eleven Biotherapeutics, Endocyte, Esperion Therapeutics, and Exelixis www.prnewswire.com - March 29 at 8:55 AM
	Esperion Therapeutics (ESPR) Study 1002-039 Phase 2 Top-Line Results - Slideshow seekingalpha.com - March 28 at 5:00 PM
	Esperion Therapeutics (ESPR) PT Set at $105.00 by Stifel Nicolaus www.americanbankingnews.com - March 28 at 3:48 PM
	Esperion Nets Another Positive Late-Stage Study Under Its Belt seekingalpha.com - March 28 at 8:57 AM
	Results Renew Optimism for Esperion Therapeutics finance.yahoo.com - March 28 at 8:57 AM
	Esperion Therapeutics (ESPR) PT Set at $88.00 by UBS www.americanbankingnews.com - March 27 at 6:48 PM
	Esperion Therapeutics (ESPR) PT Raised to $100.00 www.americanbankingnews.com - March 27 at 5:10 PM
	Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor ... globenewswire.com - March 27 at 4:55 PM
	Biohaven's IPO Roadshow Fantasy Meets Grimmer Reality www.bloomberg.com - March 27 at 4:55 PM
	Notable Tuesday Option Activity: GPRO, ESPR, INTC www.nasdaq.com - March 27 at 4:55 PM
	Esperion Therapeutics (ESPR) PT Raised to $100 at Chardan Capital Markets www.streetinsider.com - March 27 at 4:55 PM
	Will Esperion Therapeutics Inc’s (NASDAQ:ESPR) Earnings Grow In The Years Ahead? finance.yahoo.com - March 27 at 4:55 PM
	Esperion Therapeutics (ESPR) Stock Rating Lowered by Citigroup www.americanbankingnews.com - March 27 at 11:01 AM
	Esperion's drug clears study as add-on cholesterol treatment finance.yahoo.com - March 27 at 9:01 AM
	Esperion Therapeutics (ESPR) Lifted to Hold at ValuEngine www.americanbankingnews.com - March 25 at 6:25 PM
	BidaskClub Downgrades Esperion Therapeutics (ESPR) to Hold www.americanbankingnews.com - March 24 at 10:48 AM
	Esperion Therapeutics Inc (ESPR) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 18 at 3:27 PM
	-$1.45 Earnings Per Share Expected for Esperion Therapeutics Inc (ESPR) This Quarter www.americanbankingnews.com - March 11 at 8:35 PM
	Head-To-Head Comparison: AEterna Zentaris (AEZS) vs. Esperion Therapeutics (ESPR) www.americanbankingnews.com - March 11 at 6:19 PM
	Esperion Therapeutics (ESPR) Downgraded to Buy at BidaskClub www.americanbankingnews.com - March 10 at 6:34 PM
	Esperion Therapeutics (ESPR) PT Raised to $153.00 at JMP Securities www.americanbankingnews.com - March 8 at 10:31 PM
	UPDATE: Esperion reports positive results in late-stage trial of heart disease treatment , shares jump 4% - MarketWatch www.marketwatch.com - March 8 at 8:52 AM
	After A Two-Decade Quest, Will Esperion's Heart Drug Find A Market? finance.yahoo.com - March 7 at 6:01 PM
	Has Esperion Therapeutics Inc (NASDAQ:ESPR) Got Enough Cash To Cover Its Short-Term Obligations? finance.yahoo.com - March 7 at 6:01 PM
	Esperion to Participate in Fireside Chat at March 2018 Investor Conferences finance.yahoo.com - March 7 at 6:01 PM
	Esperion Tanked Despite Strong Cholesterol Drug Trial — Here's Why finance.yahoo.com - March 7 at 6:01 PM
	Esperion Releases Top Line Results For First Pivotal Phase 3 Study finance.yahoo.com - March 7 at 8:50 AM
	Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid finance.yahoo.com - March 7 at 8:50 AM
	UPDATE: Esperion reports positive results in late-stage trial of heart disease treatment , shares jump 4% finance.yahoo.com - March 7 at 8:50 AM
	23,333 Shares in Esperion Therapeutics Inc (ESPR) Purchased by Sectoral Asset Management Inc www.americanbankingnews.com - March 6 at 2:11 PM
	Is the Options Market Predicting a Spike in Esperion (ESPR) Stock? www.zacks.com - March 2 at 8:41 AM
	Ascend Capital LLC Purchases Shares of 67,241 Esperion Therapeutics Inc (ESPR) www.americanbankingnews.com - March 2 at 4:33 AM
	Esperion Therapeutics Inc (ESPR) Stake Lessened by EAM Investors LLC www.americanbankingnews.com - February 27 at 3:00 PM
	American Century Companies Inc. Invests $1.60 Million in Esperion Therapeutics Inc (ESPR) Stock www.americanbankingnews.com - February 27 at 4:06 AM
	Ontario Teachers Pension Plan Board Invests $1.64 Million in Esperion Therapeutics Inc (ESPR) Stock www.americanbankingnews.com - February 26 at 12:28 PM
	Esperion Targets $10 a Day for Heart Pill to Undercut Rivals finance.yahoo.com - February 23 at 5:33 PM
	Q1 2018 EPS Estimates for Esperion Therapeutics Inc (ESPR) Lifted by Analyst www.americanbankingnews.com - February 23 at 9:59 AM
	Stock Traders Buy Large Volume of Esperion Therapeutics Put Options (ESPR) www.americanbankingnews.com - February 23 at 8:26 AM
	Analysts Expect Esperion Therapeutics Inc (ESPR) to Post -$1.95 EPS www.americanbankingnews.com - February 23 at 3:14 AM

Esperion Therapeutics (NASDAQ:ESPR) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Esperion Therapeutics (NASDAQ:ESPR) Income Statement, Balance Sheet and Cash Flow Statement

Esperion Therapeutics (NASDAQ ESPR) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff